A large coalition of medical associations, patient advocacy groups, drug companies, and others sent a letter to Congress Monday asking that they intervene on a CMS plan to use an index based on drug prices in other countries to determine reimbursement for Part B therapies, saying it would have a negative effect on the elderly and people with disabilities.
A large coalition of medical associations, patient advocacy groups, drug companies, and others sent a letter to Congress Monday asking that they intervene on a CMS plan to use an index based on drug prices in other countries to determine reimbursement for Part B therapies, saying it would have a negative effect on the elderly and people with disabilities.
The Part B Access for Seniors and Physicians Coalition (ASP Coalition), along with 339 other groups, submitted a letter to congressional leaders urging them to block the implementation of the International Pricing Index (IPI) model announced by the Trump administration in October.
The letter urges Senate Majority Leader Mitch McConnell, R-Kansas, Senate Minority Leader Chuck Schumer, D-New York, House Speaker Paul Ryan, R-Wisconson, and House Minority Leader Nancy Pelosi, D-California, to come up with an alternate plan.
The proposed International Pricing Index would start in spring 2020 and be evaluated over the course of 5 years. CMS plans for the model to initially focus on single-source drugs and biologics. The potential model would test a payment for included drugs for when the average sales price is higher than an international price. In this instance, CMS would pay based on the target price based on the international price index.
CMS estimates that using an international price index instead of average sales price will reduce drug spending by approximately 30%. Comments are open on the proposal until December 31, 2018.
In the letter, the groups congratulate CMS for trying to strengthen competition and enhance value in Medicare Part B, but says the October proposal goes too far by making participation by Part B providers mandatory. Voluntary, small-scale reforms are fine, they said, but they believe the IPI proposal would create barriers between doctors and patients with cancer, autoimmune disorders and other complex, life-threatening conditions who rely on specialty drugs.
"The model would restrict access in the short-term, and reduce incentives for medical advancement in the long-term, ultimately posing serious risks to vulnerable Medicare beneficiaries,” the letter said. Future research and development would be harmed and control would be taken away from patients and doctors, they said.
On the day that President Trump announced the pricing index, HHS released a report comparing prices the United States paid for the top Medicare Part B drugs with the prices in other countries, including the United Kingdom, Canada, France, and Germany. The report found that prices in the United States were 1.8 times that of the average international price.
But in those countries, the letter said, access to medications are restricted by the government; in the United States, residents get access to innovative therapies 2 years earlier than patients in Europe, they said.
ASP is made up of 18 groups, including the Community Oncology Alliance, the American College of Rheumatology, Amerisource Bergen and others.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen